Open AccessBRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
Author(s) -
Cristina R. Ferrone,
Douglas A. Levine,
Laura H. Tang,
Peter J. Allen,
William R. Jarnagin,
Murray F. Brennan,
Kenneth Offit,
Mark E. Robson
Publication year - 2009
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2008.18.5546
Subject(s) - medicine , adenocarcinoma , founder effect , germline mutation , oncology , pancreatic cancer , brca2 protein , cancer , brca mutation , germline , mutation , gastroenterology , breast cancer , genotype , genetics , haplotype , biology , gene
The prognostic significance of germline BRCA1 and BRCA2 mutations in Jewish patients with pancreatic adenocarcinoma (PAC) is unknown. Our objective was to define the prevalence of BRCA1 and BRCA2 in an unselected group of Jewish patients and to compare the clinical characteristics and overall survival (OS) of patients with resected BRCA mutation-associated PAC to PAC patients without mutations.